Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 106 500 KRW -1.75% Market Closed
Market Cap: 8.7T KRW

EV/EBITDA
Enterprise Value to EBITDA

63.2
Current
48.1
Median
12.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
63.2
=
Enterprise Value
7.9T KRW
/
EBITDA
124.3B KRW
Market Cap EV/EBITDA
KR
Yuhan Corp
KRX:000100
7.9T KRW 63.2
US
Eli Lilly and Co
NYSE:LLY
776.7B USD 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
377.9B USD 12.7
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 15.1
CH
Roche Holding AG
SIX:ROG
214.5B CHF 9.7
CH
Novartis AG
SIX:NOVN
190.6B CHF 10.8
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP 131.4
US
Merck & Co Inc
NYSE:MRK
205.6B USD 8.8
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
139.3B USD 7.6
EBITDA Growth EV/EBITDA to Growth
KR
Yuhan Corp
KRX:000100
Average EV/EBITDA: 400.4
63.2
42%
1.5
US
Eli Lilly and Co
NYSE:LLY
37.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
131.4
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
43.2
2-Years Forward
EV/EBITDA
32.7
3-Years Forward
EV/EBITDA
23.3